Reproductive technology startup Orchid on Tuesday announced a comprehensive new genetic test that may help many prospective parents across the U.S. breathe a little easier.
Orchid said its new test will help couples identify whether their embryos present genetic risks such as birth defects, neurodevelopmental disorders, chromosomal abnormalities, or pediatric and adult-onset cancers that were previously only detectable after birth.
IVF is a taxing process that can cost an average of more than $12,000 in the U.S., according to the Institute for Reproductive Health.
Success is not guaranteed, and some people go through multiple rounds of IVF before a pregnancy develops.
Orchid's genetic test will cost couples an additional $2,500 per embryo sequenced, but it does not add any new steps or risks to the IVF process, Siddiqui said.
Persons:
Noor Siddiqui, Siddiqui, Couples
Organizations:
CNBC, Institute for Reproductive Health, Austin
Locations:
Dublin, Ireland, U.S, Los Angeles, Chicago, Miami